Intra-aortic Balloon Pumps (IABP) have been used for roughly 50 years in Critical Care Units,
Intensive Care Units, Cath labs as a way to improve systemic and coronary circulation in
patients in cardiogenic shock (CS) or at high risk situation as mechanical complications
stemming from myocardial infarction (MI), critical coronary stenosis, high-risk PCI, etc.
Several papers recently questioned the relevance of this assistance device - namely the
IABP-SHOCK II trial in CS and the CRISP-AMI trial in anterior MI without CS - resulting in
the downgrading of the recommendation standards of the IABP by medical societies.